Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

被引：0
|
作者：
Nikolaos Xenidis
Nikolaos Vardakis
Ioannis Varthalitis
Stylianos Giassas
Emmanouel Kontopodis
Nikolaos Ziras
Ioannis Gioulbasanis
George Samonis
Kostas Kalbakis
Vassilis Georgoulias
机构：
[1] University General Hospital of Alexandroupolis,Department of Medical Oncology
[2] University General Hospital of Heraklion,Department of Medical Oncology
[3] “Agios Georgios” General Hospital of Chania,Department of Medical Oncology
[4] “IASO” General Hospital of Athens,Department of Medical Oncology
[5] “METAXA” Anticancer Hospital of Piraeus,Department of Medical Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词：
Pegylated doxorubicin; CPT-11; SCLC; Second-line treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：63 / 68
页数：5
相关论文
共 50 条
  • [1] A multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer
    Xenidis, Nikolaos
    Vardakis, Nikolaos
    Varthalitis, Ioannis
    Giassas, Stylianos
    Kontopodis, Emmanouel
    Ziras, Nikolaos
    Gioulbasanis, Ioannis
    Samonis, George
    Kalbakis, Kostas
    Georgoulias, Vassilis
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) : 63 - 68
  • [2] Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: A phase II study
    Ichiki, M
    Gohara, R
    Rikimaru, T
    Kitajima, T
    Fujiki, R
    Shimada, A
    Aizawa, H
    CHEMOTHERAPY, 2003, 49 (04) : 200 - 205
  • [3] RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting
    Paz-Ares, L.
    Spigel, D. R.
    Chen, Y.
    Jove, M.
    Juan-Vidal, O.
    Rich, P.
    Hayes, T.
    Gutierrez Calderon, V.
    Caro, R. B.
    Navarro Mendivil, A.
    Dowlati, A.
    Zhang, B.
    Moore, Y.
    Wang, T.
    Kokhreidze, J.
    Ponce, S.
    Bunn, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S505 - S505
  • [4] Ambamustine in the second-line treatment of patients with small-cell lung cancer - A phase II Fonicap study
    Ardizzoni, A
    Antonelli, G
    Ricci, S
    Frasci, G
    Rinaldi, M
    Boni, L
    Galletti, P
    Pennucci, MC
    Antonuzzo, A
    Gravina, A
    Galli, L
    Comella, G
    Conte, PF
    Salvati, F
    Rosso, R
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (01): : 22 - 25
  • [5] Gemcitabine and Paclitaxel Combination as Second-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Phase II Study
    Dazzi, Claudio
    Cariello, Anna
    Casanova, Claudia
    Verlicchi, Alberto
    Montanari, Marco
    Papiani, Giorgio
    Freier, Eva
    Mazza, Valentina
    Milandri, Carlo
    Gamboni, Alessandro
    Papi, Maximilian
    Leoni, Maurizio
    Cruciani, Giorgio
    Vertogen, Bernadette
    CLINICAL LUNG CANCER, 2013, 14 (01) : 28 - 33
  • [6] Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
    Ettinger, David S.
    Jotte, Robert
    Lorigan, Paul
    Gupta, Vicram
    Garbo, Lawrence
    Alemany, Carlos
    Conkling, Paul
    Spigel, David R.
    Dudek, Arkadiusz Z.
    Shah, Chirag
    Salgia, Ravi
    McNally, Richard
    Renschler, Markus F.
    Oliver, Jennifer W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) : 2598 - 2603
  • [7] Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma
    Fink, W
    Zimpfer-Rechner, C
    Thoelke, A
    Figl, R
    Kaatz, M
    Ugurel, S
    Schadendorf, D
    ONKOLOGIE, 2004, 27 (06): : 540 - 544
  • [8] Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
    Eckardt, John R.
    Bentsion, Dimitri L.
    Lipatov, Oleg N.
    Polyakov, Igor S.
    MacKintosh, Frederick R.
    Karlin, David A.
    Baker, Gizelle S.
    Breitz, Hazel B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) : 2046 - 2051
  • [9] A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer
    Agelaki, S
    Syrigos, K
    Christophylakis, C
    Boukovinas, J
    Varthalitis, J
    Pavlakou, G
    Athanasiadis, A
    Kouroussis, C
    Vardakis, N
    Maltezakis, G
    Milaki, G
    Georgoulias, V
    ONCOLOGY, 2004, 66 (03) : 192 - 196
  • [10] Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
    Ardizzoni, A
    Hansen, H
    Dombernowsky, P
    Gamucci, T
    Kaplan, S
    Postmus, P
    Giaccone, G
    Schaefer, B
    Wanders, J
    Verweij, J
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 2090 - 2096
12345